Kidswell Bio Corporation · TSE:4584
Kidswell Bio — FY2021 Earnings Presentation
23 slides from Kidswell Bio's earnings presentation, May 12, 2022
Slide 1: Financial Results for FY 2021
Financial Results for FY 2021 (Fiscal Year Ended March 31, 2022) May 12, 2022 Kidswell Bio Corporation
Slide 2: Cautionary Statement
Cautionary Statement This information material is provided for understanding Kidswell Bio Corporation (“KWB”), not for soliciting investment in KWB shares. Information provided in this material may contain so-called “forward- looking statements.” These statements are based on current expectations, f
Slide 3: Business and Financial Highlights in FY 2021
Business and Financial Highlights in FY 2021 3
Slide 4: Overview of Financial and Business Highlights
Overview of Financial and Business Highlights Financial Highlights ◆ Financial Highlights in FY 2021 Full-year sales increased by biosimilar due to the addition of GBS-007. Revenues related to MCB completion shifted to FY 2022 Gross profit for the full year exceeded the forecast due to the contr
Slide 5: Consolidated Financial Results in FY 2021 (PL)
Consolidated Financial Results in FY 2021 (PL） Consolidated income statement Unit:thousands yen Results for FY2021 Subject 3Q/FY 2020 Results for GAP analysis of forecast in FY 2021 Forecast 4Q/FY 2021 Profits from GBS-001 and GBS-011 exceeded the forecasts Included sales of GBS-007 Sales of A
Slide 6: Consolidated Financial Results for FY 2021 (BS)
Consolidated Financial Results for FY 2021 (BS) Consolidated balance sheet Unit:thousands yen Subject FY2020 FY2021 Highlight Current assets 3,346,310 3,325,939 (Cash and cash Revenue from the sale of investment securities was generated, but equivalents) 1,461,158 1,187,189 investment in R&D conti
Slide 7: Financial Forecasts for FY 2022
Financial Forecasts for FY 2022 Financial Forecast Unit:thousands yen Results for FY Forecasts for Subject Highlight 2021 FY 2022 The sales of GBS-001 will decrease compared to FY 2021 due to inventory adjustments of the sales company Significant growth due to full-year sales of GBS-007 Gross sa
Slide 8: Business Forecasts for FY 2022
Business Forecasts for FY 2022 Business forecast Sales increased with the addition of GBS-007 R&D strategy shifts to focusing on growth investment while securing biosimilar-led structure for expanding and stabilizing profit Sales comparison (image chart) R&D Expenses comparison (image chart) BS（上市品）
Slide 9: Key Updates in Mid-Term Strategic Plan
Key Updates in Mid-Term Strategic Plan Key updates in 4Q/FY2021 Progressing as scheduled UPDATE! CSC Executed a share purchase Licensing-out SHED JRM-001 agreement with Metcela Inc on April 4, 2022. Development of JRM-001 is led by Metcela, Inc. Regenerative BS Forth R&D Medicine New Biologics SHED
Slide 10: Mid-Term Strategic Plan KWB 2.0 Part-1
Mid-Term Strategic Plan KWB 2.0 Part-1 All for Kids, Kids for All Kidswell Bio Corporation *Details for SHED, biosimilar and new biologics pipelines will follow as Part-2.
Slide 11: KIDS WELL, ALL WELL
Our vision All for Kids, Kids for All KIDS WELL, ALL WELL Families KIDS WELL Educational ～ For Comprehensive Healthcare System for Institutions Friends Children as well as Families, and Society ～ Focus Business areas direction Medical Pediatric diseases Targeting diseases Society Institutions includ
Slide 12: Reasons for launching KWB 2.0 - Changes in the biosimilar market
Reasons for launching KWB 2.0 - Changes in the biosimilar market - • Launched GBS-007,our third biosimilar product, as the first biosimilar in the ophthalmology field in Dec. 2021. Sales continue to be better than expected and expecting further growth • The entry of biosame (authorized biosimilar
Slide 13: Reasons for launching KWB 2.0 - Strategies for an increase in stock prices
Reasons for launching KWB 2.0 –Strategies for an increase in stock prices - The stock market didn’t evaluate KWB’s business expansion by launching biosimilars. (Yen) Bio-brand GBS-001 GBS-011 GBS-007 2800 bubble (Filgrastim BS) (Darbepoetin alfa BS) (Ranibizumab BS) 2600 2400 Launched in Nov. Launch
Slide 14: KWB 2.0 - Investment for breakthrough in SHED development
KWB 2.0 – Investment for breakthrough in SHED development - Active investment in the SHED (Cell Therapy) pipelines to promptly realize our vision • Promote global business expansion and R&D of SHED(cell therapy) • Accelerate development in overseas while continuing business in Japan • Aiming to laun
Slide 15: Business foundation for KWB 2.0
Business foundation for KWB 2.0 Step-ahead strengths among other bio ventures • Profit structure achieving sales of 3 billion yen and operating income of 1 billion yen in FY 2025 • Well-knowledge and experienced human resources in biologics development • Well-accumulated know-how in the development
Slide 16: Growth strategies for breakthrough in SHED
Growth strategies for breakthrough in SHED Launching regenerative Invention in SHED and next Commercialization medicine products of the Technology generation technology 1st generation of SHED For Launching regenerative medicine products of the For commercialization of the 2nd generation of SHED 1st
Slide 17: Breakthrough in SHED
Breakthrough in SHED - Prompt commercialization of the first generation of SHED - Selecting target diseases through Accelerating clinical development in joint research with academia Japan and overseas Based on the evidence through our R&D, Through Real World Data (RWD), Virtual further joint researc
Slide 18: Breakthrough in SHED - Investment schedule
Breakthrough in SHED - Investment schedule - Focusing on SHED development and accelerating investment for increase in corporate value Estimation Launching Non-clinical study to ～ Corporate clinical trial (Expansion of indications） 2 to 5 billion yen Japan Recruiting, development of human resource an
Slide 19: Strategic Investment in human resources and organizational structure
Strategic Investment in human resources and organizational structure • Contributing to society by the development of human resources and organizational structure that leads to an increase in KWB’s corporate value • Pursuing contributions to society (S in sustainable development goals) through the cr
Slide 20: Roadmap
Roadmap Accelerating our R&D activities to realize our vision • Accelerate SHED R&D activities to realize our vision and increase corporate value. KIDS WELL, ALL WELL • Continue stable revenue from biosimilar business and reduce manufacturing costs • Determine when to achieve profitability by priori
Slide 21: Our Role in Society
Our Role in Society Two Virtuous Cycles through “Kids Centricity” “ Medical New Medical Expenses Reduction & Treatment improvement of medial access Creating regenerative medicine More people will overcome diseases and with SHED for all generations they will play an active role in our society. Patent
Slide 22: Cautionary Statement
Cautionary Statement This information material is provided for understanding Kidswell Bio Corporation (“KWB”), not for soliciting investment in KWB shares. Information provided in this material may contain so-called “forward- looking statements.” These statements are based on current expectations, f
Slide 23: KIDS WELL, ALL WELL
All for Kids, Kids for All KIDS WELL, ALL WELL